CAR-T cell therapy: a specialist pathway, not a routine treatment.

CAR-T cell therapy is a form of cellular immunotherapy. A patient's own T cells are collected, genetically modified in a manufacturing facility so they can recognise a specific target on cancer cells, expanded in number, and then infused back into the patient after lymphodepleting chemotherapy.

Depending on the specific product, regulatory approval and specialist assessment, CAR-T therapy may be considered for selected patients with certain relapsed or refractory hematologic malignancies, such as some B-cell leukaemias and lymphomas and multiple myeloma. Not all indications are approved in every country, and CAR-T is not an option for most cancers.

No. CAR-T is a cell therapy, not chemotherapy. However, lymphodepleting chemotherapy is usually given before the CAR-T infusion, and bridging chemotherapy is sometimes needed while the cells are being manufactured.

T cells are collected from the blood by leukapheresis, verified for identity, sent to a manufacturing facility where the chimeric antigen receptor is introduced, expanded, tested for quality and then released for treatment. Manufacturing is carried out by the relevant product facility, not at the bedside.

The overall pathway usually spans several weeks — assessment, cell collection, manufacturing, lymphodepletion, infusion and close monitoring — followed by long-term follow-up. Exact timelines depend on the product, the treating centre and the patient's clinical condition.

Recognised risks include cytokine release syndrome, neurological toxicity (ICANS), prolonged low blood counts, serious infections, low immunoglobulin levels, bleeding, tumour lysis syndrome, prolonged immune suppression, delayed complications and, rarely, severe or fatal events. Risks are discussed in detail during specialist assessment.

Cytokine release syndrome (CRS) is an inflammatory response that can follow CAR-T infusion. Features may include fever, low blood pressure, rapid heart rate, low oxygen levels, fatigue and, in severe cases, organ dysfunction. CRS can become serious or life-threatening and requires immediate specialist management — patients should not attempt to assess or grade it themselves.

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological complication that can follow CAR-T therapy. Possible symptoms include confusion, altered behaviour, difficulty speaking, changes in handwriting, reduced alertness and, in severe cases, seizures. Any neurological symptom after CAR-T requires urgent medical assessment.

CAR-T therapy requires specialised infrastructure and close supervision. Depending on the product, protocol and treating centre, admission and a period of staying close to the centre are usually required. This is not a routine day-care infusion.

Eligibility cannot be determined from a website or by patients themselves. It depends on confirmed diagnosis, disease status, previous treatment, organ function, infection status, disease burden, product availability and regulatory indication, and is decided through specialist hematology-oncology assessment — often in coordination with an authorized cellular-therapy centre.